ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Therapy of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) targeting the BCR::ABL1 kinase has become a paradigm for precision oncology.